最近的研究表明，程序性细胞死亡配体 1 (PD-L1) 表达与各种实体瘤的不良预后相关，但其与胰腺癌的临床相关性尚未明确。这项荟萃分析总结了 PD-L1 在胰腺癌中的潜在预后价值。通过系统搜索数据库（包括 PubMed、EMBASE、Web of Science、Cochrane 图书馆、Scopus 和 Ovid）进行定量荟萃分析，以查找有关 PD-L1 对胰腺癌患者预后意义的合格研究。计算汇总风险比 (HR) 及其 95% 置信区间 (CI)，以评估 PD-L1 表达与患者临床预后之间的联系强度。我们的研究纳入了 17 项符合条件的研究，涉及 2669 名患者。胰腺癌患者的 PD-L1 丰度与较差的总生存期 (OS) 之间存在显着相关性，合并风险比 (HR) 为 1.902，95% CI：1.657-2.184。敏感性分析证实了我们结果的可靠性。亚组分析显示，PD-L1 的区域和检测方法的差异并没有改变 PD-L1 对胰腺癌患者不良预后的总体预测价值。这项荟萃分析表明，PD-L1 的表达与胰腺癌患者的 OS 较差相关。此外，PD-L1 可能作为预测不良预后的潜在参数，从而为胰腺癌的抗癌治疗提供有前景的靶点。

Recent studies revealed that programmed cell death ligand 1 (PD-L1) expression was associated with unfavorable prognosis in various solid tumors, but its clinical relevance for pancreatic cancer has not yet been well established. This meta-analysis summarizes the potential prognostic value of PD-L1 in pancreatic cancer. A quantitative meta-analysis was performed by a systematic search of databases including PubMed, EMBASE, Web of Science, Cochrane library, Scopus and Ovid for eligible studies on the prognostic significance of PD-L1 in pancreatic cancer patients. Pooled hazard ratios (HRs) and their 95% confidence intervals (CIs) were calculated to evaluate the strength of the link between PD-L1 expression and clinical prognosis of patients. Seventeen eligible studies with 2669 patients were included in our study. A significant association was observed between PD-L1 abundance and poor overall survival (OS) of patients with pancreatic cancers, with a pooled hazard ratio (HR) of 1.902, 95% CI: 1.657-2.184. Sensitivity analysis confirmed the reliability of our results. Subgroup analysis shows that differences in regions and detection methods of PD-L1 did not change the overall predictive value of PD-L1 for poor prognosis in pancreatic cancer patients. This meta-analysis indicated that the expression of PD-L1 is associated with a worse OS in pancreatic cancer patients. Additionally, PD-L1 may act as a potential parameter for predicting poor prognosis and thus providing a promising target for anticancer therapy in pancreatic cancer.